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ABSTRACT In this study, we propose a structure for the heterodimer between apolipoprotein A-IMilano and apolipoprotein A-II
(apoA-IM–apoA-II) in a synthetic high-density lipoprotein (HDL) containing L-a-palmitoyloleoyl phosphatidylcholine. We applied
bioinformatics/computational tools and procedures, such as molecular docking, molecular and essential dynamics, starting from
published crystal structures for apolipoprotein A-I and apolipoprotein A-II. Structural and energetic analyses onto the simulated
system showed that the molecular dynamics produced a stabilized synthetic HDL. The essential dynamic analysis showed a
deviation from the starting belt structure. Our structural results were validated by limited proteolysis experiments on HDL from
apoA-IM carriers in comparison with control HDL. The high sensitivity of apoA-IM–apoA-II to proteases was in agreement with the
high root mean-square ﬂuctuation values and the reduction in secondary structure content frommolecular dynamics data. Circular
dichroism on synthetic HDL containing apoA-IM–apoA-II was consistent with thea-helix content computed on the proposedmodel.
INTRODUCTION
The lipoproteins are macromolecular complexes of lipid and
protein, a major function of which is to transport lipids
through the vascular and the extravascular body ﬂuids. High-
density lipoproteins (HDLs), the smallest and most dense
lipoproteins, are involved in the reverse transport of choles-
terol and exert antiatherogenic activities (1). The major pro-
tein component of HDL is apolipoprotein A-I (apoA-I) (2).
The majority of HDL is spherical and contains other apo-
lipoproteins, such as apoA-II and the C peptides, nascent
HDLs are discoidal particles and contain two molecules of
apoA-I (3).
Crystal structures for lipid-free apoA-I (4,5) and apoA-II
(6) have been solved, but it is well known that these
amphipathic proteins are structured and exert their activity
solely in a lipidic environment (7). For this reason, two alter-
native theoretical models, based on amphipathic a-helices,
have been proposed for the tertiary structure of lipid-bound
apoA-I. In the picket-fence model (8), the helices run anti-
parallel to one another (intramolecular protein-protein inter-
actions) and parallel to the lipid acyl chains; in the belt (or
rail-fence) model (9), the helices run perpendicular to phos-
pholipids (intermolecular protein-protein interactions). A
hairpin folding has also been proposed (10), with most he-
lices perpendicular to the phospholipid acyl chains and a
random head-to-tail and head-to-head arrangement of the
two apoA-I molecules. During the last years, the most
credited model was the belt, but a recent article by Culot et al.
(11), in which a synthetic HDL (s-HDL) was directly ob-
served by scanning tunneling microscopy, better agrees with
the picket-fence arrangement for apoA-I and other apolip-
oproteins. Molecular dynamics (MD) of a discoidal complex
made of L-a-palmitoyloleoyl phosphatidylcholine (POPC)
and a synthetic a-helical 18-mer peptide with an apolipo-
protein-like charge distribution in a picket-fence arrange-
ment has been run for 700 ps (12).
Apolipoprotein A-IMilano (apoA-IM), the ﬁrst described
mutant of apoA-I (13), differs from wild-type protein by the
single amino-acid substitutionR173C, leading to the formation
of homodimers (apoA-IM–apoA-IM) and of heterodimers
with apolipoprotein A-II (apoA-II) (apoA-IM–apoA-II) (14).
Carriers of the mutant, all heterozygous, show a very low
plasma HDL-cholesterol level and a moderate hypertriglyc-
eridemia (15), but they do not differ to any extent in the
entity of carotid intima-media thickness with respect to close
relatives living in the same environment and with HDL
levels in the normal range (16). These observations suggest a
peculiar protective effect for the apoA-IM. The mutant apo-
lipoprotein was selected in its homodimeric form as a drug
for the treatment of atheromatous cardiovascular disease, now
in clinical development (17). The apoA-IM–apoA-IM homo-
dimer has both a very powerful cholesterol-removing ca-
pacity (18) and peculiar plasma kinetic characteristics, with a
residence time after a single parenteral administration longer
than eight days (19). In this study, we focused our attention
onto the structure of the apoA-IM–apoA-II heterodimer, which
can contribute, together with the apoA-IM–apoA-IM homo-
dimer, to the cardiovascular protective effects. A puzzling
feature we could demonstrate in our investigation is a pe-
culiar susceptibility to proteolysis that suggests a different
and more ﬂexible conformation than for wild-type apoA-I.
To obtain a model for the apoA-IM–apoA-II molecule we
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applied bioinformatics/computational tools and procedures,
starting from published crystal structures for apoA-I (4) and
apoA-II (6). The model was used to build an s-HDL con-
taining two molecules of apoA-IM–apoA-II and 112 mole-
cules of POPC as homogeneous phospholipid bilayer. The
MD of this macromolecular complex was computed for 15 ns
in explicit solvent to obtain data about the structural and
dynamic properties of the antiatherogenic mutant protein
apoA-IM, in the heterodimeric form and in a lipidic en-
vironment, an essential preliminary step for understanding its
biological activity.
MATERIALS AND METHODS
In vitro experiments: proteolysis
Human HDL3 (d ¼ 1.125–1.21 g/ml) were separated from plasma of fasting
healthy volunteers by salt density ultracentrifugation. ApoA-IM HDL3 was
puriﬁed from carrier plasma. Control and apoA-IM HDL3 (0.1 mg of protein/
ml) were mixed with trypsin at the ratio of 1:50 (w/w) and incubated at 37C.
At various time intervals, aliquots were removed, SDS was added to obtain
a ﬁnal concentration of 4%, and samples were boiled for 2 min to terminate
the reaction. The digestion products were analyzed by SDS-PAGE on 10–
16% acrylamide gradient slab gels, using the Tris/HCl//Tris/tricine buffer
system (20).
Puriﬁcation of plasma A-IM–A-II
HDLs (d ¼ 1.063–1.21 g/ml) were isolated from apoA-IM plasma by
sequential ultracentrifugation. After delipidation, HDL apolipoproteins were
solubilized in 0.1 M Tris-HC1, 0.04% EDTA, 0.01% NaN3, pH 7.4,
containing 6 M GdnHCl and applied to a Sephacryl S-300 HR column (2.6
3 300 cm) (Pharmacia Biotech, Uppsala, Sweden) equilibrated with 0.1 M
Tris-HC1, 0.04% EDTA, 0.01% NaN3, pH 7.4, containing 4 M GdnHCl.
Fractions corresponding to apoA-IM–apoA-II were concentrated and
reapplied to the same column. The purity (.95%) of apoA-IM–apoA-II
preparation was conﬁrmed by SDS-PAGE, using Coomassie protein
staining. Aliquots of apoA-IM–apoA-II were stored at 80C in lyophilized
form. Before use, apoA-IM–apoA-II was dissolved in 20 mM phosphate
buffer, pH 7.4, containing 6 M GdnHCl and extensively dialyzed against 20
mM phosphate buffer, pH 7.4.
Synthetic HDLs containing A-IM–A-II and palmitoyloleoyl phosphati-
dylcholine (POPC) were prepared by the cholate dialysis technique (starting
weight ratio of 2.5:1) (21). In the ﬁnal preparation, all the protein was incor-
porated into stable s-HDL, with no lipid-free apolipoprotein remaining.
Circular dichroism (CD) spectra were recorded with a Jasco J500A
spectropolarimeter at the constant temperature of 25C (Jasco, Tokyo, Japan).
Molar mean residue ellipticity (u) was expressed in degrees 3 cm2 3
dmol1, and calculated as: u ¼ uobs 3 115 / 10 3 l 3 c, where uobs is the
observed ellipticity in degrees, 115 is the mean residue molecular weight of
the proteins, l is the optical path length in cm, and c the protein concentration
in g/ml. All the spectra were baseline-corrected. The a-helical content was
calculated by the method of Chang et al. (22).
In silico simulations: preparation of the
apoA-IM molecule
ApoA-IM was obtained by introducing the R173C mutation in A and B
chains of wild-type apoA-I (PDB ID code: 1AV1, corresponding to amino
acids 43–243 of the protein primary structure) (4) with the Biopolymer
module of the Insight II suite (Accelrys, San Diego, CA). The rotamer
library for cysteine was then manually explored and the most favorable
energetic arrangements were selected. Another apoA-I structure (PDB ID
code: 2A01) was deposited during the writing of this article (5). However, it
could not have been used in our modeling procedures, because its four-helix
bundle structure is not suitable to accommodate lipid molecules.
Preparation of the heterodimer
apoA-IM–apoA-II molecule
ApoA-IM (A and B chains) was docked with apoA-II (PDB ID: 1L6L
corresponding to amino acids 4–77 of the protein primary structure) (6)
(J and T chains) by using ZDOCK (23) with default parameters. One-
hundred solutions were generated for each A–J, A–T, and B–J chain pairs.
The solutions were examined and only the complexes with a sulfur-sulfur
distance, 12 A˚ between C173 in apoA-IM and C
6 in apoA-II were accepted.
The selected complexes (three for the A–J, two for the A–T, and three for the
B–J pairing, third column in Table 1) were subjected to energy minimization
(EM) with MOE (Chemical Computing Group, Quebec, Canada), using the
CHARMM22 (24) force ﬁeld, down to a root mean-square (RMS) gradient
of 0.001 kcal/mol A˚; a distance-dependent dielectric term (e ¼ 4r) was
applied, as in Vitale et al. (25). After EM, for each chain pairing the complex
with the lowest total energy was selected and submitted to a further MD of
5 ns (fourth column in Table 1). The lengths of the bonds involving the
hydrogen atoms were constrained according to the SHAKE algorithm,
allowing for an integration time step of 2 fs. The velocities at 300 K were
randomly assigned from the Maxwell-Boltzmann distribution. Restraints
were set as 2.7 A˚ minimum- and 3.0 A˚ maximum-allowed distance between
the backbone oxygen atom of residue i and the backbone nitrogen atom of
residue i14. As reported in Vitale et al. (25), by reducing the system degrees
of freedom the application of these intrahelical distance restraints is in-
strumental in preserving the secondary structure of a-helices. Only the A–J
complex proved stable during the MD simulation (seventh column in
Table 1). EM and MD were carried out with MOE on a two-processor Apple
Power Mac running Apple Mac OS X version 10.3.
Preparation of the (apoA-IM–apoA-II)2 molecule
Two molecules of heterodimer apoA-IM–apoA-II (A–J) were docked by
using ZDOCK (23) with default parameters. One-hundred solutions were
generated and visually examined. The only two arrangements compatible
with a central phospholipid (POPC) core were energy-minimized as de-
scribed above in detail.
Preparation of the s-HDL particle
The structure with the lowest energy was used for setting up the system for
the molecular dynamics simulation. The preparation of the s-HDL particle
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required a large and equilibrated double layer of POPC: a 32 3 32 lipid-
molecule equilibrated bilayer was obtained from the free-access database of
bilayer structures of Peter Tieleman (http://moose.bio.ucalgary.ca/) and used
to create manually a larger bilayer of 64 3 64 POPC molecules. This novel
membrane structure was energy-minimized, solvated with water in a 16 3
16 3 16 nm3 box, and minimized again; then its dynamics was simulated
for 2 ns to get an equilibrated structure and to avoid any boundaries artifact.
The (apoA-IM–apoA-II)2 molecule was placed into the double layer while
getting as many lipid molecules as possible trapped into the hole formed
by the ringlike dimer structure, in agreement with relevant experimental data
about s-HDL composition (26). The lipid molecules remaining outside
the hole were manually removed using the Insight II suite, running on SGI
Fuel, with the aid of Stereo Graphics Crystal Eyes stereo view. The resulting
s-HDL particle, containing 112 POPC molecules, was inserted in a 15 3
15 3 15 nm3 box that was then ﬁlled with water. The system was neutral-
ized by adding 20 Na1 ions, minimized, and then simulated in two differ-
ent steps: 1), 500 ps of position-restrained MD with an isotropic force
(1000 kJ mol1 nm2) applied to all protein atoms to allow for both water
exit from the hydrophobic bilayer core and solvent relaxation; and 2), 15 ns
of unrestrained MD. Analysis of the trajectory was started after the ﬁrst
nanosecond of unrestrained MD and carried out over the following 14 ns.
The software package GROMACS 3.2.1 was used, both on local Apple Mac
OS X-based machines for few ps trial runs and on the Avogadro Linux
supercomputer at Consorzio Interuniversitario Lombardo per l’Elaborazione
Automatica for the main simulation. GROMOS96 force ﬁeld, modiﬁed
according to Berger et al. (27) to improve lipid properties, was applied;
single-point charge water model was used for the simulation of explicit
solvent.
All the simulations were performed at 300 K and 1 bar with coupling con-
stant of 0.1 ps for temperature and 1.0 ps for pressure, in both cases applying
the Berendsen weak coupling algorithm. The time step for integration was
set at 0.001 ps.
A twin-range cutoff of 1.0/1.7 nm for the treatment of both Coulomb and
van der Waals interactions was used with neighbor list searching (updated
every 10 steps).
Changes of axis orientation during MD in contiguous a-helices were
monitored with the program g_helixaxis (28,29). Criteria for the selection of
the structures to be monitored were: a-helix in crystal structure, motion in
essential dynamics, distance from chain termini, and close proximity to next
a-helix.
RESULTS AND DISCUSSION
Limited proteolysis has been applied to the study of apoA-I
in different types of HDL and reconstituted lipoprotein, for
structural, topological, and functional purposes. Maximal
susceptibility of lipid bound apoA-I to proteolytic attack
has been mapped in various experimental setups to the
N-terminus (30,31), to the middle part (32–34) or to the
C-terminus of the molecule (33–35). This variability hints at
major plasticity of apoA-I, whose conformation appears to
depend on the size of the carrier particle, mode of recon-
stituted HDL preparation, type of added lipid and oxidation
state of methionine residues. HDL3, obtained both from
control subjects and from carriers of the Milano mutation,
were digested with trypsin in a time-course setup; the pattern
of the resulting proteolytic fragments is shown in Fig. 1.
ApoA-II seems to be very resistant to trypsin in both the
tested samples. In the apoA-IM containing HDL3 the sus-
ceptibility to proteolysis increases in the order: apoA-I ,
apoA-IM–apoA-II , apoA-IM–apoA-IM.
Proteolysis of a native protein is kinetically regulated
by the differential accessibility of the various target amino
acids to the enzyme. The apparent unrestrained availability
to proteolytic enzymes of a larger number of target sites in
homo- and heterodimeric apoA-IM forms, with respect to
wild-type apoA-I, thus suggests relevant structural differ-
ences exist between them. Availability of the recombinant
protein already allowed characterization of the apoA-IM–
apoA-IM homodimer (36). In both 7.8 and 12.5 nm s-HDL
particles containing the dimer, the a-helical content of apoA-
IM is similar to that of apoA-I in small size wild-type HDL
(26). Susceptibility to proteolysis of apoA-IM–apoA-IM is
much higher than for apoA-I, cutting sites being recognized
at speciﬁc positions in the middle and C-terminus (34). This
observation suggests that two amino-acid stretches in a-helix
structure in apoA-I are instead disordered in the homodimer,
in contrast with the suggestion that apoA-I and apoA-IM in
HDL share the same belt structure (2). ApoA-IM–apoA-II
heterodimer is an abundant component of A-IM HDLs and
likely contributes to their protective effects, yet it cannot be
synthesized in vitro with acceptable yields and as such is not
amenable to direct characterization. Models of the molecular
components peculiar to the A-IM HDLs, the apoA-IM–apoA-
IM homodimer, and the apoA-IM–apoA-II heterodimer, to
be compared with models of apoA-I in wild-type discoidal
HDL, would help in understanding the biochemical and
physiological implications of the apoA-IM mutation. As
detailed inMaterials andMethods, we built in silico an s-HDL
FIGURE 1 Pattern of trypsin proteolysis for apoA-IM (a) and control (b)
HDL3, as analyzed by SDS-PAGE. HDL3 were incubated with trypsin at
37C (enzyme/substrate ratio, 1:50); at various times, 10 mg of protein was
removed, the reaction was terminated, and the digestion products were
separated by SDS-PAGE.
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containing two molecules of apoA-IM–apoA-II, through the
following steps:
Step 1. R173C mutation from wild-type apoA-I to
apoA-IM.
Step 2. Molecular docking between apoA-IM and apoA-II
and disulﬁde bonding to form the heterodimer.
Step 3. Molecular docking between two molecules of
apoA-IM–apoA-II.
Step 4. Bounding with (apoA-IM–apoA-II)2 an equili-
brated bilayer of POPC to form the s-HDL.
From the published structures of apoA-I in octameric
stacked form (4), chains A and B were selected as inputs
because they have a shape dissimilar from one another. For
apoA-II crystallized in multimeric form (6), chain J was pre-
ferred as having the curvature closest to apoA-I crystal, and
chain T as having the curvature most different from apoA-I.
At each Step 2–4, selection among the solutions was ﬁrst on
the basis of geometrical consideration (appropriate sulfur-
sulfur distance in Step 2, formation of a ringlike structure in
Step 3), then on the basis of energetic ranking. The potential
energy of the geometrically acceptable structures after each
step is charted in Table 1. Fig. 2, a–c, shows the result of the
above docking procedures. Panel a is a top view of the pro-
tein chains without lipids, i.e., after Step 3 of the above se-
quence of procedures. Panel b is a top view and panel c is a
side view of the s-HDL after Step 4, before the 15-ns MD
was started. Figs. 3 and 4 (except for panel d) show the evo-
lution with time of some structural and energetic parameters
of the system during MD. All parameters plateau during the
last stage (in no case less than the last 5 ns) of the simulation.
Gross geometrical stability is attained early in the sim-
ulation process: backbone net displacement as measured by
a-carbon RMSD already quenches after 4 ns to reach a pla-
teau after 8 ns (Fig. 3 c). Radius of gyration decreases down
to its minimal stable value of ;4.2 nm after 8 ns (Fig. 3 d).
This size is fully compatible with actual properties of apoA-
IM s-HDL, as known from literature data (26).
The number of interactions among protein chains (number
of H-bonds in Fig. 4 a) increases by;0.1-fold during the ﬁrst
100 ps of simulation but then merely ﬂuctuates; the number
of salt bridges does not change with time (not shown). On the
contrary, the number of interactions between protein and
lipids keeps growing, to a 2.5-fold increase at 15-ns versus
start of MD (Fig. 4 b).
Also the protein-protein interaction energies only slightly
change with simulation time (not shown). On the contrary,
the protein-lipid interaction energies decrease until plateau is
reached at ;7 ns for short-range Coulomb (Fig. 4 c) and at
;9 ns for Lennard-Jones energies (Fig. 4 d). This evidence
leads to the conclusion that the increasing number of contacts
between apolipoproteins and POPC acts as the driving force
for the structural reorganization of the s-HDL during the
simulation. The number of amino acids in secondary struc-
ture (Fig. 3 a) gradually decreases by ;8%, equally distrib-
uted among the four protein chains, and approaches plateau
at ;12 ns. We can conclude that the polypeptide chains are
substantially less structured in the s-HDL containing (apoA-
IM–apoA-II)2 than in the starting crystal structures.
For this most critical feature of the model, experimental
proof was sought. A CD spectrum on an s-HDL reconstituted
from plasma-puriﬁed apoA-IM–apoA-II and POPC (Fig. 6
in Supplementary Material) measures, at 222 nm, a molar
mean-residue ellipticity of 24.70 mdeg, corresponding to a
helix content of 74%. A DSSP run (37) on the last minimized
time frame recognizes in the model 391 aa in a-helix, 9 aa in
3-helix, 13 aa in 5-helix, for an overall helix content of 75%
across a total of 548 aa in s-HDL. For the structure content in
(apoA-IM–apoA-II)2, the agreement between computed and
found is thus excellent.
The plot of RMSF (Fig. 3 d) shows two peaks of ﬂuc-
tuation corresponding to the C-termini of the apoA-IM chains.
FIGURE 2 Model structure for (apoA-IM–
apoA-II)2 in an s-HDL containing 112 POPC
molecules. (a–c) Before MD; (d–f) after 15-ns
MD. Panels a and d identify the four apo-
lipoprotein chains (color code: yellow for
apoA-IM(A), red for apoA-II(A), blue for
apoA-IM(B), and cyan for apoA-II(B); labels
near the N-termini), the remaining panels
identify the two apoA-IM–apoA-II hetero-
dimers (color code: yellow for (A), blue for
(B)). Panels a, b, d, and e are top views; c and
f are side views. Protein structure is rendered
as a-carbon ribbon, POPC with CPK colors
(image made with Discovery Studio 1.5,
Accelrys).
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The decrease in structure (Fig. 3 a) and the increase in
protein ﬂexibility (Fig. 3 d) demonstrated by MD closely
agree with the ﬁnding of higher susceptibility to proteolysis
seen in Fig. 1. Due to the 4 A˚ resolution of the crystal (4), no
direct comparison of B-factor with the ﬁnal structure of
apoA-IM–apoA-II is possible. The cleavage by trypsin of
apoA-IM and apoA-IM–apoA-IM was extensively character-
ized with mass spectrometry (34). Interestingly, most of the
cleavage sites are located in high RMSF regions on the sim-
ulated apoA-IM molecule; furthermore apoA-IM has several
other high RMSF regions, which can explain the proteolytic
susceptibility of this mutant in its heterodimeric arrangement.
The structure of (apoA-IM–apoA-II)2-containing s-HDL
after 15 ns MD is shown in Fig. 2, bottom. By pairwise
comparison of Fig. 2, d–f, with a–c, some of the features
already inferred from physical parameters are apparent. The
C-termini of apoA-IM(A) and (B) get closer to the lipid core
while becoming less ordered; the overall structure becomes
more compact. The course of the protein chains becomes
tilted to a lower angle to the direction of the phospholipid
acyl chains.
Our MD and ED results in Fig. 5 a suggest the apo-
lipoprotein chains bend with time around four hinges. As a
result, the protein increases its out-of-plane deformation,
markedly deviating from a planar belt conformation. The
positions of the four hinges correspond to regions in which
the number of adjacent apolipoprotein chains lowers by one
(at individual chain termini), allowing for higher ﬂexibility
of the system. All hinges encompass proline residues [apoA-
II(A) P32, apoA-II(A) P74, apoA-I(B) P99, and apoA-I(B)
P143]. Fig. 5 c details the changes with time of the angle
between two pairs of contiguous a-helices—aa 88–98 vs.
99–120 and aa 121–142 vs. 143–164 in apoA-IM(B)—to
which the criteria for the treatment with g_helixaxis (28,29)
could be applied (see under Materials and Methods). At the
beginning of MD the tilt between the helices is;45 in both
pairs. This value increases to only ;50 for 88–98 vs. 99–
120 but to as much as to;70 for 121–142 vs. 143–164. The
s-HDL structure packs in during the simulation time, and
twisting is unevenly distributed along the apolipoprotein
sequence. A very recent article (38) compared the results of
4–7 ns MD simulations of nanodiscs, similar to s-HDL,
containing a ﬁxed number of phospholipid molecules—160
DPPC per particle, according to Bayburt et al. (39) and
Denisov et al. (40)—and various truncated forms of wild-
type apoA-I. With the 200-amino-acid-long truncated form,
extensive ﬂexibility of the protein scaffold resulted in a se-
vere out-of-plane deformation of apoA-I chains. With forms
shorter by 11- and 22-amino acids, a planar belt structure
was on the contrary observed for the protein scaffold. A
planar belt structure had also been observed in the 1-ns MD
FIGURE 3 Geometrical and structural properties of (apoA-IM–apoA-II)2
s-HDL from MD run data. (a) Number of amino-acid residues in secondary
structure; (b) radius of gyration; (c) RMSD; and (d) RMSF. Amino-acid num-
bering is according to the primary structure of apoA-I (shaded background)
and apoA-II (open background). Data from the last 14 ns of simulation.
FIGURE 4 (a,b) H-bonding pattern of (apoA-IM–apoA-II)2 s-HDL from
MD run data. (a) Number of protein-protein H-bonds; (b) number of protein-
lipid H-bonds. Data from the last 14 ns of simulation. (c,d) Energetic
properties of (apoA-IM–apoA-II)2 s-HDL from MD run data. (c) Coulomb
short-range protein-lipid interaction energy; (d) Lennard-Jones protein-lipid
interaction energy. Data from the last 14 ns of simulation.
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simulation of an s-HDL containing two 211-amino-acid-long
truncated form of apoA-I and 160 molecules of POPC (2).
From these data, the phospholipids/protein ratio seems cru-
cial for the structure of s-HDL in solution.
When building the heterodimer-containing s-HDL, most
POPC molecules were added to our system with an au-
tomated script, but number and position of phospholipids
were then manually reﬁned. One-hundred-and-twelve POPC
molecules could be placed inside the protein ring. This
phospholipids/protein ratio is very close to the experimental
value (61:1) observed for s-HDL containing the 200-amino-
acid-long truncated form of apoA-I (38). During our sim-
ulation, no phospholipid moved away from the s-HDL and
the changes with time in lipid-lipid and protein-lipid energies
(Fig. 4, c and d) conﬁrmed a favorable rearrangement toward
a more stable particle.
All of this direct and indirect evidence: stability with MD
time of the in silico-generated structure, agreement between
calculated and measured parameters, and conformity of ex-
perimental behaviorwith simulated features, are supportive to
the value of the (apoA-IM–apoA-II)2 model we propose. The
reported ﬁndings are suggestive that the apoA-IM–apoA-II
heterodimer, one of the major component of HDL in the
carriers, may possibly act as a decoy substrate for proteases
upon entering the artery wall from the circulation, thus
exerting a local protection against proteolytic activity, which
leads to plaque rupture. In this way, the apoA-IM carriers,
having HDL very active in cholesterol removal and with a
long half-life in plasma as well as acting as high-afﬁnity
substrates for proteolytic enzymes in the arterial wall, would
be provided with a highly vasoprotective lipoprotein fraction.
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